News

21 Oct HP&C’s Mike Heim featured in Law360 article analyzing the role of patent law in the drug-pricing debate

Posted at 19:17h in News

Law 360 recently interviewed Heim, Payne & Chorush co-founder and managing partner Mike Heim for an analysis examining the role of patent law and regulation in the escalating debate over drug-pricing. The analysis by Law360 senior reporter Ryan Davis explores a number of recent legislative proposals,...

19 Oct Texas Super Lawyers Honors Four from Heim, Payne & Chorush

Posted at 19:15h in News

Patent litigation veterans selected by peers for statewide recognition HOUSTON – Four partners from Heim, Payne & Chorush have been named among the state’s top attorneys in the 2020 ranking by Super Lawyers, a prestigious guide that recognizes no more than 5 percent of Texas attorneys...

07 Jul Heim, Payne & Chorush Named Among Best Law Firms for Patent Litigation

Posted at 15:13h in News, Patent Litigation

Firm, four partners honored by London-based IAM 1000 HOUSTON – Patent litigation boutique Heim, Payne & Chorush has been recognized among the top intellectual property law firms by London-based publisher IAM for 2020. In addition, firm partners Michael Heim, Les Payne, Russell Chorush and Eric Enger...

24 Mar COVID-19 UPDATE

Posted at 15:03h in News

Thank you for visiting Heim, Payne & Chorush. Due to the COVID-19 virus, we have opted to close our offices for the safety of our employees, our clients, our co-tenants and our city. Please be assured that the entire HPC team continues to work remotely....

23 Mar Fractus Reaches Patent Infringement Settlement with ZTE after Favorable Court and PTAB Rulings

Posted at 08:00h in News

Heim, Payne & Chorush has successfully settled another patent infringement lawsuit on behalf of Spanish antenna technology company Fractus, S.A. The settlement with Chinese telecommunications corporation ZTE closes the book on a patent infringement lawsuit filed in 2017 over claims that ZTE had infringed on...

03 Mar Texas Lawyer Article: HP&C’s Blaine Larson analyzes recent Federal Circuit decisions shaping the Section 101 patent eligibility landscape

Posted at 16:46h in News

While the U.S. Supreme Court recently declined to consider three closely watched patent eligibility appeals, recent decisions by the U.S. Court of Appeals for the Federal Circuit are providing valuable guidance regarding patent eligibility under Section 101, Heim, Payne & Chorush Partner Blaine Larson writes...

14 Jan Christopher First Promoted to Partner at Heim, Payne & Chorush

Posted at 11:52h in News

Heim, Payne & Chorush congratulates Christopher First on his promotion to partner. Since joining the firm in 2015, Chris’s cutting-edge tech, scientific and legal expertise have made him a key member of the HPC team in complex litigation involving patent infringement and patent-related antitrust litigation, as well as inter partes review (IPR) at the U.S. Patent...

09 Dec Heim, Payne & Chorush Earns National Honor for Patent-Related Antitrust Litigation Against Big Pharma

Posted at 15:51h in News

Trailblazing firm involved in many of a generation’s largest pharma antitrust outcomes HOUSTON – The American Antitrust Institute (AAI) has honored intellectual property litigation firm Heim, Payne & Chorush (HPC) with its 2019 Antitrust Enforcement Award for Outstanding Antitrust Litigation Achievement in Private Law Practice. The award...

22 Nov Heim, Payne & Chorush Named Among Nation’s Best by US News – Best Lawyers

Posted at 11:01h in News

Patent, intellectual property litigation firm earns top honors for 2020 HOUSTON – Patent litigation boutique Heim, Payne & Chorush has been named among the best law firms in the nation for patent infringement and intellectual property litigation for 2020 by U.S. News & World Report and The Best Lawyers in America. In addition to national recognition, the...

29 Oct Brand-Name Drug Company Allergan Agrees to Pay Record $750M to Settle Antitrust Claims Based on Alleged Hatch-Waxman Abuses

Posted at 16:36h in News

Settlement is largest for a single defendant in an antitrust case involving delayed market entry of generic drugs NEW YORK – A class of wholesale drug distributors has reached a record $750 million settlement resolving antitrust claims based on anticompetitive conduct related to the Alzheimer’s...